Jhl Biotech Hong Kong Ipo

Jhl biotech hong kong ipo

JHL will allocate its new capital to support clinical trials and further development of its biosimilar portfolio.

Jhl biotech hong kong ipo

JHL Biotech, a Taiwan developer of cheaper alternatives to patent-protected biological drugs, has raised $106 million from a convertible bond issue, ahead of its planned Hong Kong initial public offering (IPO) aiming to raise some $250 million.

JHL will allocate its new capital to support clinical trials and further development of its biosimilar portfolio. Earlier this year, JHL completed a voluntary de-listing of its Taiwan shares, a transaction that allowed shareholders to retain ownership of their holdings.

JHL is among at least two other non-mainland companies that have been preparing or mulling to tap the Hong Kong stock exchange’s equity-raising channel that was recently broadened to allow pre-revenue biotechnology firms to list for the first time.

Sign up for the editor pick and get articles like this delivered right to your inbox.



Hong Kong's 2019 IPO Pipeline Is Very Strong, Says HKEX's Li